In eukaryotic cells, protein disulfide bond formation occurs in the lumen of the ER as part of the folding and assembly process for newly synthesized secretory proteins. A pathway formed by the oxidoreductases ERO1 (ER oxidoreductin 1) and protein disulfide isomerase (PDI) drives the thiol--disulfide equilibrium in the ER toward disulfide bond formation ([@bib12]; [@bib8]). PDI directly catalyzes the formation of disulfides in secretory proteins, accepting electrons from thiols in folding nascent chains. To sustain additional rounds of protein disulfide formation, PDI transfers these electrons to ERO1. In turn, ERO1 passes its electrons to molecular oxygen and/or alternate acceptors in the cell.

Despite an overall conservation of the ERO1--PDI pathway among eukaryotes, important differences exist between organisms. Although many simple eukaryotes like *Saccharomyces cerevisiae* and *Caenorhabditis elegans* encode a single ERO1, mammals contain two ERO1 isoforms, ERO1-α and -β. At present, no major differences in redox activities or substrate interactions have been identified between the characterized human paralogues. Continuing this trend, in this issue, Zito et al. show that the two mouse ERO1 proteins have similar in vitro biochemical activities. Distinct tissue distribution and transcriptional regulation for the ERO1 isoforms has suggested the potential for unique contributions toward disulfide bond formation in the cell ([@bib7]; [@bib2]). However, the actual redundancy and/or specificity for the ERO1 isoforms in vivo has remained an open question. [@bib15] begin to address this issue by focusing on the roles of ERO1-α and -β in mice. Their experiments suggest a selective, nonredundant function for ERO1-β in oxidative protein folding in insulin-producing cells. Their work also provides the first indication as to how ERO1 activity impacts the development of individual tissues, advancing our knowledge of the role for ERO1 in oxidative folding in the animal.

The work of [@bib15] primarily focuses on ERO1-β, which has been the lesser characterized of the two isoforms. Using antisera specific for each of the mouse ERO1 isoforms, they observe tissue-specific expression of the mouse isoforms similar to that previously reported for the human ERO1s ([@bib7]; [@bib2]). Most striking was a strong and selective staining for ERO1-β in the pancreas. In contrast, ERO1-α was detected in all tissues. To study the cellular activity of ERO1-β, [@bib15] developed a mouse model homozygous for an insertion in intron 14 of the *Ero1lb* locus that compromised ERO1-β expression in the pancreas. Disruption of ERO1-β resulted in defective oxidative folding in the ER; in particular, homozygous mutant mice showed a kinetic delay in the processing of disulfide-bonded proinsulin to insulin. As might have been anticipated by this delay in the folding of disulfide-linked insulin, loss of ERO1-β function adversely impacted insulin biogenesis and glycemic control in mice. By 3 mo of age, the majority of homozygous mutant mice showed a stable diabetic phenotype.

A surprise came upon further characterization of the residual oxidative folding observed in the homozygous ERO1-β mutant, which might have been expected to be a product of the activity from the remaining ERO1 isoform. Remarkably, the residual disulfide-linked folding of insulin does not depend on ERO1-α; no enhancement in phenotype was observed with concomitant disruption of both the *Ero1l* and *Ero1lb* loci. Considering that the ERO1 genes in both *S. cerevisiae* and *C. elegans* are essential for viability, the viability of the mutant mouse lacking both isoforms of ERO1 is quite surprising. These observations suggest that ERO1-β serves as an islet-selective isoform of ERO1 that enhances the oxidative folding capacity of insulin-producing cells. At least in the pancreas, the two ERO1 isoforms appear nonredundant. An additional unexpected result came with the analysis of the oxidative folding for immunoglobulin-producing cells in the double mutant mouse that revealed only a modest delay in the oxidative folding of IgM. As the authors propose, this provides strong evidence for an important ERO1-independent mechanism for generating disulfide bonds in mammals. What accounts for the residual activity remains an open question.

Only three classes of enzymes that can couple small molecule redox chemistry to the de novo formation of disulfides have been identified in the ER: ERO1, VKOR, and the ERV/QSOX superfamily. VKOR catalyzes the reduction of vitamin K, which is ultimately required for proper blood coagulation. It has been suggested that the catalytic cycle of VKOR is coupled with oxidative folding in the ER via PDI ([@bib14]). The ERV/QSOX superfamily consists of disulfide bond--forming catalysts that share a common flavin-binding domain that is found either alone (ERVs; [@bib3]) or fused with a PDI-like domain (QSOX family; [@bib10]). Erv2 is the only ER-localized ERV protein and is a fungal-specific enzyme that can operate parallel to ERO1 in the yeast ER to introduce disulfide bonds into substrate proteins ([@bib9]). Erv2 is not present in mice. However, proteins of the QSOX family are present in vertebrates, plants, and protists. Mammalian QSOX enzymes were first characterized as extracellular proteins; however, recently, QSOX isoforms have been localized to the ER/Golgi region ([@bib13]; [@bib1]). It will be interesting to determine whether QSOX or VKOR enzymes account for the oxidizing power remaining in the ER of mammalian cells lacking ERO1 ([Fig. 1](#fig1){ref-type="fig"}). Intriguingly, genetic data in flies suggest that a member of the QSOX family may contribute to disulfide bond formation when the function of the single *Ero1l* gene in the fly is compromised ([@bib11]). Future efforts in the field will surely focus on the further characterization of alternate (and perhaps novel) oxidase systems beyond ERO1 in the ER lumen and how these additional pathways relate to the ERO1--PDI pathway.

![**Pathways for oxidative folding in the ER of *Mus musculus*.** Mice contain two ERO1 isoforms (α and β) that use PDI and/or PDI-like proteins (PDI(s)) to oxidize substrates. ERO1-β has a specific impact on the oxidative folding of insulin in the mouse pancreas ([@bib15]). VKOR and QSOX proteins may also facilitate oxidative folding in the ER, although their connections to folding in the ER lumen are less well established. VKOR, QSOX, or alternative unidentified pathways in the ER, including small molecules, may allow for the oxidative folding of IgM in the absence of ERO1 activity.](JCB_201002114_RGB_Fig1){#fig1}

At a broader level, the work of [@bib15] also highlights the challenge in reconciling an understanding of redox homeostasis in cultured cells with the additional complexities present in a whole animal. Alteration of ERO1 activity has been shown to help cells cope with redox imbalances in the ER of yeast and worms ([@bib4]; [@bib5]; [@bib6]). In keeping with these prior studies, [@bib15] observed that knockdown of ERO1-β in cultured Min6 cells strongly protected cells from toxicity of an insulin mutant defective for oxidative folding (proinsulin^Akita^). However, the benefits caused by a decrease in ERO1 activity in cultured cells were not observed in pancreatic cells of live mice; the diabetic phenotype of the proinsulin^Akita^ mutation was accentuated by genomic disruption of ERO1-β expression. The authors put forth several distinctions between cultured cells relative to tissues in the animal that may contribute to the differences observed in cell culture relative to the whole animal, including differences in oxygen levels and/or developmental programs. Alternatively, these disparities may relate to experimental differences: a stable disruption of ERO1-β in the mouse (disrupted throughout development) relative to a transient RNAi knockdown in the cultured system. Importantly, elucidating the contributing factors toward the different phenotypic outcomes of the loss of ERO1 activity will be an important step toward understanding how redox imbalances are offset in the whole organism.
